Celcuity Inc is a biotechnology company focused on transforming the treatment of cancer by advancing its proprietary Celcuity Platform, which is designed to identify specific cellular behaviors that drive the disease. The company aims to develop innovative targeted therapies by leveraging insights from patient-derived tumor samples. By utilizing its unique approach, Celcuity seeks to enhance the precision of cancer treatment, ultimately improving patient outcomes through personalized medicine. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Celcuity (CELC) reported Q2 2025 results with a wider-than-expected EPS loss but revenue in line. Clinical progress in breast cancer trials drives investor optimism despite financial misses.
Peraso Inc. (NASDAQ: PRSO), a leader in 60GHz mmWave wireless technology, is rapidly expanding its global footprint through dual momentum in defense and broadband sectors. In a key commercial milestone, Tachyon Networks has selected Peraso’s PRM2141X module for its new TNA-303L-65 —a compact outdoor wireless solution delivering fiber-class speeds up to 1 Gbps across 3+ km, without the need for costly trenching.
Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.”
